scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111 BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today that it has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111. The SCP-111 formulation is the subject of a supplemental NDA expected to...
scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remains on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $40.8 million as of June 30, 2025 Investor conference call and webcast today, Thursday, August 7th, at 4:30pm ...
A Closer Look at FY2Q25 (June) ResultsRevenueTotal revenue of $1.004 billion (up 48% y/y and 14% q/q), came in above both the company’s guidance range of $934.0 million to $938.0 million and the Street’s $939.3 million estimate as the company continues to see unprecedented demand for AIP and growth
scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025 Management to host conference call and webcast, after-market on August 7, 2025, at 4:30 p.m. ET BURLINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 7, 2025, to discuss the financial results for the ...
Teladoc Health Reports Second Quarter 2025 Results NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended June 30, 2025 (“Second Quarter 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended June 30, 2024 (“Second Quarter 2024”). Highlights Second Quarter 2025 revenue of $631.9 million, down 2% year-over-yearSecond Quarter 2025 net loss of $32.7 million, or $0.19 per shareSecond Quarter 2025 adjusted EBITDA of $69.3 million,...
BCB Bancorp, Inc. Earns $3.6 Million in Second Quarter 2025; Reports $0.18 EPS and Declares Quarterly Cash Dividend of $0.16 Per Share BAYONNE, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank”), today reported net income of $3.6 million for the second quarter of 2025, compared to a net loss of $8.3 million in the first quarter of 2025, and net income of $2.8 million for the second quarter of 2024. Earnings per diluted share for the second quarter was $0.18 compared to a loss of ($0.51) per dil...
BCB Bank announces Daniel A. Araujo’s promotion to Senior Vice President and Chief Lending Officer BAYONNE, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- BCB Bank is proud to announce the promotion of Daniel A. Araujo to Senior Vice President and Chief Lending Officer. This promotion is in alignment with BCB’s customer-first approach and dedication to organizational excellence. Mr. Araujo brings more than 20 years of industry knowledge and lending management experience to the Bank. Araujo is a highly respected industry veteran who brings a wealth of experience and an entrepreneurial mindset to...
Wedbush Securities’ affiliated investment adviser, Wedbush Fund Advisers, LLC (“WFA”), may serve as the investment adviser to certain investment funds that track an index comprised exclusively of companies included in this research report. In connection with these funds, Wedbush Securities will rec
Teladoc Health to Announce Second Quarter 2025 Financial Results NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release second quarter 2025 results on Tuesday, July 29, 2025, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. ET on the same day. Conference Call DetailsThe conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 606269. For international participants, please visit the follow...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.